Adherence to Viral Load Testing Guidelines, Barriers, and Associated Factors Among Persons Living with HIV on ART in Southwestern Uganda: a Mixed-Methods Study. by Lubega, Polly, Nalugya, Sylivia Juliet, Kimuli, Angella Namyalo, Twinokusiima, Majoreen, Khasalamwa, Mercy, Kyomugisa, Richard, Kabami, Jane, Owaraganise, Asiphas

“…Background: Uganda adapted Viral load (VL) testing for monitoring HIV treatment success and virologic failure. However, there is a paucity of data on how the VL testing guidelines are followed in practice in HIV clinics. …”
Get full text

Fitness costs of Mycobacterium tuberculosis resistant to rifampicin is compensated by rapid Th2 polarization mediated by early and high IL-4 production during mice infection by Ma. Fernanda Arce-Aceves, Roberto Espinosa-Neira, Dulce A. Mata-Espinosa, Jorge A. Barrios-Payan, Hugo G. Castelán-Sánchez, Sofía L. Alcaraz-Estrada, Mauricio Castañón-Arreola, Rogelio Hernández-Pando

Get full text

Peer-assisted telemedicine hepatitis-C treatment for people who use drugs in rural communities: a mixed methods study by Kim Hoffman, Gillian Leichtling, Sarah Shin, Andrew Seaman, Tonhi Gailey, Hunter C. Spencer, P. Todd Korthuis

“…The Oregon HOPE TeleHCV study randomized PWUD living with HCV in rural Oregon to peer-facilitated and streamlined telemedicine HCV treatment (Peer TeleHCV) versus enhanced usual care (EUC) and assessed sustained virologic response at 12 weeks post treatment (SVR12). …”
Get full text

HIV viral load suppression rates among adults and children living with HIV in the North West Region of Cameroon: A call for action! by Gladys Fosah E Tayong, Melissa Sander, Comfort Vuchas, Moses Samje, Vera Kum, Pascal Enokbonong, Eugene Yeika, Ndanga Bekombo, Paul Nyibio, Vanessa B Ngwani, Justin Ndié, Njamnshi Wepnyu Yembe, Gloria Ashuntangtang

“…In this study we hypothesized that the virologic outcome of children living with HIV is unfavorable compared to adults.…”
Get full text

Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamid... by Bruno Emond, Carmine Rossi, Aurélie Côté-Sergent, Keith Dunn, Patrick Lefebvre, Marie-Hélène Lafeuille, Prina Donga

“…**Methods:** The Symphony Health, IDV® database (July 17, 2017 – September 30, 2019) was used to identify treatment naïve or virologically suppressed stable switchers who initiated DRV/c/FTC/TAF or BIC/FTC/TAF (index date) on or after July 17, 2018, were ≥18 years of age on the index date, and had ≥12 months of continuous clinical activity pre-index (baseline period). …”
Get full text

Long-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir by Shana Yi, David Truong, Brian Conway

“…In the GRAND PLAN, we documented sustained virological response post-treatment Week12 (SVR12) in 108/117 (92.3 %) individuals (108/111 (mITT) or 97.3 % of those reaching the SVR12 timepoint) receiving an 8-week course of glecaprevir/pibrentasvir (G/P), with almost all using fentanyl and over half being unstably housed. …”
Get full text